Biomarker testing is crucial for personalized oncology care, aiding in risk stratification and treatment decisions, but faces ...

Biomarker testing is changing how colorectal cancer is treated, giving patients more personalized and effective care. By ...

New global initiative urges patients and clinicians to wait for biomarker testing results before starting treatment.

Oncology pharmacists bridge gaps in test ordering, result interpretation, and therapy access, ensuring timely and effective ...

Precision Care Companion (PCC) enhances biomarker testing and precision therapy adoption in community oncology, uniting practices, labs, and biopharma for improved patient outcomes. PCC focuses on ...

Cancer is often caused by genetic mutations, which can lead to abnormal cell growth in the body. One type is called the KRAS G12C mutation, which happens in the KRAS protein.[1] KRAS acts as the ...

Not available to all in New Jersey, biomarker testing is used to analyze samples of blood, tissue and other bodily fluids to identify specific genes, proteins and more that can indicate the presence ...

Imagine this: someone you love has just heard the words “you have cancer.” They are meeting with their oncologist – perhaps even me, or one of my colleagues – and come to understand that there is ...

‘I Tried Midi Health for Biomarker Testing—Here’s What I Learned About My Health’ originally appeared on Parade. Considering that I’m a journalist, it’s not a surprise that I believe that knowledge is ...

Although treatment of advanced gastroesophageal cancer is increasingly dependent on biomarkers, only about 40% of patients are tested. For patients to fully benefit from the latest targeted therapies, ...

Across all cancer types, less than 50% of patients underwent biomarker testing before first-line treatment. Many patients with advanced cancer do not receive guideline-recommended biomarker testing ...

Please provide your email address to receive an email when new articles are posted on . Biomarker testing appeared inconsistent, with rates not reflecting guidelines. Less than 25% of oncologists ...